A Science Foundation Ireland founded Strategic Research Cluster in association with DCU, UCD, TCD, RCSI and ICORG


04 May 2011

Funding Awarded to MTCI


MTCI Researchers Secure €6 Million EU Funding: AngioPredict


Annette Byrne PhD

(MTCI Funded Researcher, Lecturer Dept of Physiology & Medical Physics, Royal College of Surgeons in Ireland)

We are pleased to announce further funding success to MTCI Investigators from the most recent Call of the  European Commission funded Framework Programme 7 (FP7) initiative. The recently successful FP7 Health application ANGIOPREDICT was co-ordinated by Dr Annette Byrne  [MTCI Funded Investigator & Lecturer, Graduate Entry Programme & Dept of Physiology and Medical Physics, RCSI].
The project  seeks to develop predictive genomic biomarkers methods for combination   bevacizumab (avastin) therapy in metastatic  colorectal cancer  and integrates the combined efforts of nine European partners across academia, industry and clinical research. Total funding awarded was c.6 million Euros with c. 2.9 million going to Irish MTCI partners [ RCSI, UCD, ICORG] & the newly spun-out Irish SME ONCOMARK Ltd.



MTCI Investigator Successful in EU Funded Research Project: Angiotox


MTCI investigator successful in EU funded research project to investigate toxicity mechanisms of approved anti-angiogenesis cancer drugs

The 'Angiotox' project is coordinated by Dr. Annette Byrne, Royal College of Surgeons in Ireland (RCSI) and Director of Translational Research at OncoMark.

The ‘Angiotox’ project will investigate the toxicity and mechanism of action of anti-angiogenic drugs used in the treatment of cancer patients. The project, worth €1.75 million euro, is funded under the FP7 Marie Curie Industry Academia Pathways and Partnerships scheme, and will bring together 7 partners from around Europe including partners at F. Hoffman La Roche and Zeptosense- a division of Bayer.

"In this wide-ranging project, we have assembled complementary research groups across Europe from both academic and industry sectors, which will work closely together via intersectoral exchanges to mediate key new insights into anti-angiogenic drugs. These funds will go toward ensuring we understand the mechanism of these drugs with a view towards translating this information for patient benefit." commented Dr. Byrne.

The goal of this consortium is to facilitate comprehensive histopathologic and mechanistic assessment of angiogenesis inhibitor related toxicities following treatment with the two main class of angiogenesis inhibitor; monoclonal antibodies and tyrosine kinase inhibitors.



MTCI Investigator Awarded €6 Million Funding by EU


MTCI Investigator awarded €6 million funding by the EU to investigate possible treatments for difficult-to-treat types of Breast Cancer.

Professor William Gallagher of University College Dublin has been awarded €6 million by the EU to investigate possible treatments for difficult-to-treat types of breast cancer.

“At present, there is a lack of targeted therapies for two poor-prognosis subtypes of breast cancer namely ‘triple negative’ breast tumors and invasive lobular carcinomas of the breast,” says Professor William Gallagher from the UCD Conway Institute who is leading this research. “Together these subtypes make up almost 25% of all breast cancers.”

“Our research will explore the role of kinases – the key regulators of cell function - in these types of breast cancer in order to develop therapeutic targets that may inhibit the rate of activation of kinases in cancer sufferers.”